How to Maintain Velocity Without Sacrificing Quality
Interview with Qualio Founder and CEO Robert Fenton
Fast, good, or cheap — you can only pick two, so which will it be? It’s a common question, but it’s probably not one that’s best suited for the medtech and healthtech industries.
For many, quality is viewed as a hurdle, slowing a project’s velocity, but Robert Fenton founder and CEO at Qualio is determined to change that reality for companies developing life-saving products.
While working in drug development for some of the world’s largest pharmaceutical companies, including Pfizer and LEO Pharma, Robert observed how an organization moves an idea from bench science to proof of concept and beyond.
“What really struck me is that companies make a clinical promise: First, do no harm,” he says. “If you’re working on a medical device that’s going to diagnose or treat something really important, it must be safe, it must work effectively, and it must work consistently, which is, essentially, the promise of quality.”
Robert set out to develop a cloud-based quality management system that would help life sciences companies launch and scale their life-saving products without sacrificing quality or slowing down the multistage process.
In this episode of Medsider, Robert shares his predictions for the life sciences industry in 2022. He also discusses how Qualio can support (and not hinder) medtech and healthtech companies as they move through the complex process of taking a product from conception to the market.
You May Like These Articles
Medsider Premium
Become a premium member and unlock access to exclusive Medsider benefits.